| HOME >> BIOLOGY >> TECHNOLOGY |
NOVATO, Calif., Feb. 28, 2012 /PRNewswire/ -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the FDA Office of Orphan Products Development has granted orphan drug designation for UX003 for the treatment of MPS 7. MPS 7 is an extremely rare autosomal recessive lysosomal storage disorder characterized by a deficiency of the lysosomal enzyme Beta-glucuronidase, required for the degradation of the glycosaminoglycans dermatan sulfate (DS) and heparan sulfate (HS). UX003 is a recombinant human Beta-glucuronidase intended as an enzyme replacement therapy for the treatment of MPS 7. MPS 7 was originally described in 1973 by William Sly, MD, St. Louis University School of Medicine, and is also known as Sly Syndrome. Ultragenyx in-licensed the MPS 7 program from St. Louis University. su
"Obtaining orphan drug designation for UX003 is a significant achievement for Ultragenyx that adds value to our development pipeline and attests to the importance of this product candidate in filling an unmet medical need," said Emil D. Kakkis, MD, PhD, Chief Executive Officer of Ultragenyx. "We look forward to continuing to collaborate with Dr. Sly and colleagues at St. Louis University to advance this urgently needed therapy into clinical testing."
The Orphan Drug Designation program provides orphan status to drugs and biologics intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S. Among the benefits of orphan designation in the US are seven years of market exclusivity following FDA approval, waiver or partial payment of application fees, and tax credits for clinical testing expenses conducted after orphan designation is received.
About MPS 7
Mucopolysaccharidosis type 7 (MPS 7), also known as Sly syndrome, is a rare gen
'/>"/>
| SOURCE Ultragenyx Copyright©2010 PR Newswire. All rights reserved |
Related biology technology :
1. NanoLogix Instructs Third-Party to Prepare US FDA Submittals and is Granted US and Chinese Patents
2. BioDrain Medical, Inc. Granted Canadian Patent for its Streamway® Surgical Fluid Management System
3. Cephalon Granted Temporary Restraining Order in AMRIX® Patent Litigation
4. Ganeden Biotech Granted 100th Probiotic Patent
5. Biomerix Granted US Patent for Its Proprietary Biomaterial Platform Technology
6. EmergingMed Granted Patent
7. Spectral granted IDE approval by U.S. FDA to conduct pivotal trial for Toraymyxin(TM)
8. Appeal of Lawsuit by Former Officer Dismissed; Request for Sanctions Granted
9. YM BioSciences granted two US patents for AeroLEF(R)
10. Viron granted U.S. Patents for Organ Transplant and Arthritis Drug Candidates
11. Hahnemann University Hospital Granted Magnet(R) Status
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |